• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Signos raises $20M for AI-powered CGM tech with backing from Google Ventures, Dexcom Ventures

October 25, 2023 By Sean Whooley

Signos CGM technology
The AI-powered CGM technology in use. [Image courtesy of Signos]
Signos announced that it raised $20 million in a Series B round to support its AI-powered continuous glucose monitor (CGM) technology.

San Francisco-based Signos develops a comprehensive metabolic health platform. It includes a proprietary AI engine with a CGM to provide real-time data and recommendations for weight management. Signos aims for its metabolic-led solution to reverse prediabetes and aid those on their weight loss journey.

Previously only available for non-diabetics, the company expanded its platform to support people with type 2 diabetes earlier this year.

The company says its new funding round helps it expand its core team and platform, plus conduct additional research. Cheyenne Ventures and Google Ventures led the round, while Dexcom Ventures and Samsung Next also contributed.

Signos’ app enables members to log what they eat and how much they exercise. It enables the AI platform to learn how a metabolism reacts to different foods and fitness patterns. The offering then provides data-driven, personalized recommendations based on an individual’s unique metabolic profile.

“Sleep, stress, exercise, and diet all influence how high and sustained one’s glucose spikes can be,” CEO Sharam Fouladgar-Mercer said. “We often don’t realize that people make around 227 food-related decisions a day. By providing glucose visibility, tracking and AI-driven proactive suggestions, Signos can help you navigate those choices for better health.”

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup, Patient Monitoring, Technology Tagged With: Signos

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS